European Society of Cardiology’s Post

🫀 Enhancing Cardiovascular Care with AVC Detection: Addressing Stroke Risk in TAVR Patients A recent study by Dr. Jabagi, Dr. Kim, Dr. Zapolanski, Dr. Grau, et al. found that using cerebral protection systems (CPS) after TAVR did not significantly reduce stroke incidence at 30 days or one year post-TAVR, particularly when used on healthier, low-complexity patients. 🔗 https://lnkd.in/eU7MZC3f The Challenge: It's crucial to identify at-risk patients early before TAVR becomes the only option 💡 Our Solution? The Bunkerhill Health AVC Detection Algorithm*! Integrated into non-gated chest CT workflows, this algorithm detects and quantifies Aortic Valve Calcium (AVC). Detecting AVC early allows for timely intervention, reducing the need for TAVR in the first place, thus lowering the likelihood of procedural strokes. As TAVR is used more in younger, low-risk populations, early detection is essential for safer, more effective cardiovascular care. *pending FDA clearance #StructuralCardiology #TAVR #AorticStenosis #StrokePrevention #AIinHealthcare

The American Heart Association and American College of Cardiology Joint Committee have released a report on the 2024 clinical performance and quality measures for adults with valvular and structural cardiovascular disease. Healthcare professionals can visit the link to review the report published in the peer-reviewed journal, Circulation: Cardiovascular Quality and Outcomes: https://lnkd.in/d_x_wBhn #CardiovascularCare #HeartHealth #ValvularDisease #StructuralHeartDisease #ClinicalPerformance #QualityMeasures #MedicalResearch #HealthcareQuality

Insights from Dr. Anita Ann Sunny Pharm D, BCPS Ane Sunny's Session on Stroke at the 2nd National CP Summit 2024 Attending Dr. Anita Ane Sunny's session on Stroke Management was an enlightening experience that deepened my understanding of this critical area in healthcare. Here are some key takeaways: Key Learnings: 1.Types of Strokes and Pathophysiology: - Cardioembolic strokes and their distinct characteristics. - The role of small vessel occlusion, often linked to hypertension. - Large artery disease driven by lipid abnormalities and its implications. 2.Differentiating Thrombus Types: - Atherothrombotic (white) clots predominantly consists of platelets. - Embolic (red) clots are usually associated with blood components. - The concept of “Comi" – interaction between platelets and coagulants forming red-on-white clots. 3.Therapeutic Approaches: - Importance of Dipyridamole and Newer Oral Anticoagulants in treatment. - Adopting liberal blood pressure targets for large vessel diseases (150/80 mmHg) by using less potent antihypertensives for hypertensive emergency during stroke. 4.Medication Adherence: - Reinforced the critical role of ensuring patients adhere to prescribed medications for optimal outcomes. This session not only enhanced my clinical knowledge but also reinforced the importance of a holistic and patient-centric approach to stroke management. Immense gratitude to Dr. Anita for delivering such a comprehensive and impactful session! #StrokeManagement #ClinicalPharmacy #CPSummit2024 #HealthcareInnovation #PharmacyEducation

🩺 “We improved care for over 3000 chest pain patients, and we're particularly proud to have reduced the door-to-balloon time in the STEMI equivalent cohort by 13 hours.” – Martin Herman, CEO of Powerful Medical. At the American Heart Association Health Tech Competition 2024, Martin introduced PMcardio, our AI-powered cardiovascular diagnostics platform. Trained on millions of patient outcomes, PMcardio diagnoses 39 cardiac conditions from any 12-lead ECG. Central to PMcardio is our AI-powered chest pain pathway, designed to transform acute heart attack care. By improving detection accuracy, streamlining care in clinical settings and reducing false positives, it sets a new standard in cardiovascular diagnostics. 🎥 Watch Martin’s winning presentation to learn more about PMcardio transforming cardiac care. #AHA2024 #PowerfulMedical #AIInHealthcare

McKinsey & Company produces a report on value-based Care with some interesting insights. Notably, cardiovascular care lags in value-based agreements even though hospital avoidance and readmission reduction are areas of opportunity, particularly for heart failure. At the Cardiac Care Alliance, we enable cardiology groups to benefit from their work in value-based agreements. We'll even take the risk for you. Let's talk. P.S. we bring cardiology to ACOs and Primary Care groups in value-based agreements too.

Really intrigued to see the following publication by Dr. Maznyczka et al in JACC: Cardiovascular Interventions: https://lnkd.in/eCftFuHY The prospective-registry based study (low-to-intermediate risk patients, n = 1216) focused on commercially available balloon-expandable TAVR. Key takeaway points are: 1. "High" TAVR stent "asymmetry" (uneven stent height upon expansion, i. e. non-uniform expansion) resulted in impaired hemodynamic function (defined as residual gradient >= 20 mm Hg and/or moderate or greater PVL) before hospital discharge. 2. Moderate or severe hemodynamic valve deterioration was similar in high vs. low TAVR asymmetry patients (median follow-up 407 days). 3. High TAVR asymmetry was not associated with all-cause mortality and cardiovascular mortality at 30-day, 1-year, and 5-year follow-up. The underlying theory/concept "verified" by the study results is not that novel and is well understood from a valve-design-and-functionality perspective. In a way, the study essentially points out the limitations of "foreshortening" TAVR stent and how it can impact valve function. Similar results were reported by Dr. Mangels et al back in 2018: https://lnkd.in/exDhgn8D #TAVRasymmetry #impairedhemodynamics #impactofforeshortening

💛 National Cholesterol Education Month - September 2024 💛 Stay informed during National Cholesterol Education Month by exploring Cardiology CME/CE Conferences and Online Courses on the eMedEvents platform - https://bit.ly/49cVENw 🔍 High cholesterol is a major risk factor for heart disease and stroke, contributing to approximately 4.4 million deaths worldwide each year. With cardiovascular diseases as the leading global cause of death, healthcare professionals must stay updated on the latest cardiology advances through continuous education. Staying informed on new research and treatment strategies is key to effectively managing cholesterol-related health issues and improving patient outcomes. Advance your cardiology expertise on the eMedEvents platform. #CholesterolAwareness #CardiologyCME #HeartHealth #MedicalEducation #eMedEvents

Patients with a small annulus in the aortic valve of the heart – the ring-like base of the valve that supports its leaflets – face challenges when undergoing transcatheter aortic valve replacement (TAVR). These patients, many of them women, are at greater risk for a host of poor outcomes. Now, the largest, randomized, controlled TAVR trial to primarily enroll women has some answers to address this. Results of the SMART trial, comparing self-expanding and balloon-expandable TAVR valves in patients with a small annulus, were recently published in the New England Journal of Medicine, with UH Harrington Heart & Vascular Institute’s Guilherme Attizzani, MD, Interventional Director of the Valve and Structural Heart Disease Center, as study co-author and steering committee member. Dr. Attizzani also holds the Alexander and Marianna McAfee Endowed Chair in Innovative Cardiovascular Intervention. SMART trial results show advantages for the self-expanding valve – already in regular use at UH for patients with a small annulus. But Dr. Attizzani says the study is likely to have wide impact elsewhere and cause clinicians who haven’t typically used these devices to take a second look. Read more at https://lnkd.in/gzz42n9v #TAVR #SMARTtrial #womenshealth #hearthealth #physicianexcellence #patientsfirst

🌟 #ESCCongress 2024 Highlights: Insights from Hotline 8 Session🌟 🔹 #SENIOR-RITA Trial: The largest trial to date in patients aged 75+ with #NSTEMI. While no significant reduction in cardiovascular death or non-fatal MI was observed with an invasive strategy, there was a notable reduction in non-fatal MIs and revascularization procedures. These results empower older patients and clinicians to make informed decisions on invasive management. 🔹 #EARTH-STEMI: This meta-analysis revealed that complete revascularization significantly reduces cardiovascular events compared to culprit-only revascularization in older patients with #STEMI and multivessel disease, with a similar safety profile. Long-term benefits, however, still require further follow-up. 🔹 #SCOFF Trial: Challenging conventional wisdom, this study found that patients who did not fast before cardiac catherisation procedures had no increase in complications and reported higher satisfaction. These findings could lead to updated guidelines, prioritizing patient comfort without compromising safety. These studies collectively pave the way for refined treatment strategies and improved patient care in cardiology.

💡 “We are in an era of finding coronary disease, before we can see it...This (inflammation) is developing high-risk plaque (HRP), and HRP is something we know has a 5-fold risk of rupture in 5-years. Let’s stop heart attacks and let’s start understanding coronary inflammation,” shared Prof. Nehal Mehta, our esteemed Scientific Advisory Board member and Director of Inflammatory Risk and Preventive Cardiology at the Hospital of the University of Pennsylvania. 🔎 He discussed the potential of CaRi-Heart FAI-Score and its application in tracking the impact of the new anti-inflammatory drug, orticumab, during ACC'2024 with Cardiovascular Business. 👉 https://lnkd.in/dAjjnbEN #CardiovascularHealth #InnovationInMedicine #CardiacCT #cardiovasculardisease #heartattack #inflammation #FAIScore Abcentra American College of Cardiology #ACC2024